60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

RedChip will air sponsored interviews with 60 Degrees Pharmaceuticals and Exyn Technologies on Bloomberg TV and CNBC, highlighting clinical, commercialization and autonomous-robotics initiatives. 60 Degrees has enrolled the minimum 24 patients needed for an interim babesiosis trial analysis due in October 2026; management cites a potential U.S. market of up to 380,000 annual patients, $245 million in peak annual sales and $1.1 billion in cumulative revenue through 2035 if tafenoquine is approved. Exyn reported more than 1,000 autonomous missions per month and cited a mining deployment that reduced scan time from roughly 40 minutes to five while increasing coverage about 300%, alongside expanding government and defense opportunities. The release is promotional content from a compensated investor-relations provider, with no new financial results or independently validated clinical data.

Analysis

This is paid investor-relations distribution rather than independently validated fundamental news, so the likely near-term effect is retail attention and volatility—not a durable rerating. SXTP has a discrete October clinical-data event, but a 24-patient interim readout has unusually wide confidence intervals; the relevant valuation swing will turn on effect size, safety—particularly hemolysis risk inherent to tafenoquine in G6PD-deficient patients—and FDA agreement that the dataset can support a registrational path. The stated commercial opportunity should be heavily discounted until payer coverage, diagnostic capture, and an appropriately screened eligible population are established.

For EXYN, the more investable mechanism is conversion from project deployments to repeatable software/OEM revenue. GPS-denied autonomy is strategically valuable, but mining customers can have long procurement cycles and defense enthusiasm does not equal funded programs; Green UAS status and named contract awards would matter more than mission-volume claims. If EXYN proves recurring software revenue, gross-margin expansion and lower hardware intensity could differentiate it from drone hardware peers such as AVAV and RCAT; absent that evidence, defense-autonomy multiples are premature.

Consensus retail response may overvalue television reach and underweight financing/liquidity risk common to microcaps and warrants. A transient post-broadcast spike is more probable over days than fundamental price discovery. SXTP's October readout and EXYN's certification/contract milestones create 1-3 month catalysts, while either company needs 6-18 months of audited revenue, cash runway, and customer-conversion evidence to justify a structural rerating.

Key Decisions for Investors

• No core position based solely on the broadcast; avoid chasing either SXTP or EXYN in the first 1-2 trading sessions, when promotional-flow volatility and thin liquidity can dominate.
• SXTP event watch: consider a small, defined-risk long only after confirming cash runway through the expected FDA interaction and reviewing interim endpoint, adverse-event, and G6PD-screening disclosure. Falsify on non-supportive efficacy/safety data, a requirement for a materially larger trial, or financing announced at a steep discount.
• EXYN watch-list long only on independently disclosed contract value, backlog, recurring software mix, and Green UAS certification; seek entry after any promotional spike retraces rather than before. Falsify if government activity remains pilot-scale, gross margin fails to improve with OEM adoption, or quarterly cash burn implies near-term dilution.
• For liquid defense-autonomy exposure while EXYN evidence matures, prefer AVAV or RCAT only if new U.S. procurement awards validate the broader GPS-denied autonomy budget cycle; this captures the theme with materially lower single-name financing risk.